| Literature DB >> 36096829 |
Ziyang Yu1, Jie Ding2, Huize Pang3, Hongkun Fang1, Furong He1, Chenxi Xu1, Xuedan Li4, Ke Ren5,6,7.
Abstract
BACKGROUND: To investigate the value of computed tomography (CT)-based radiomics model analysis in differentiating renal oncocytoma (RO) from renal cell carcinoma subtypes (chromophobe renal cell carcinoma, clear cell carcinoma) and predicting the expression of Cytokeratin 7 (CK7).Entities:
Keywords: Cytokeratin 7; Radiomics; Renal cell carcinoma; Renal oncocytoma; Support vector machine
Mesh:
Substances:
Year: 2022 PMID: 36096829 PMCID: PMC9469588 DOI: 10.1186/s12894-022-01099-0
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.090
Fig. 1Flowchart illustrates patient recruitment
Fig. 2Workflow of radiomics methodology. (1) The example of tumor segmentation on the CT image of a cross-axial section. The contours were drawn slightly within the borders of the tumor. The tumor was segmented on both corticomedullary and nephrographic phase images, respectively. Thus, VOI was generated by a continuous layer of delineation. (2) Six types of radiomics features were analyzed via AK software. (3) LASSO was applied in the training set for feature selection. (4) The models were evaluated by ROC curve analysis. SHAP values were applied with the SVM models to transparentize the “black box.” (5) A nomogram that incorporates radiomics signature and clinical factors was constructed to provide a visual measure for customized evaluation, followed by decision curve analysis and calibration curve
Statistical analysis of the representative radiomic features derived from the combination
| Feature names | chRCC | RO | ccRCC | F-value/ |
|---|---|---|---|---|
| HaralickCorrelation_angle135_offset7_NP | 2.90E+08 ± 2.26E+08 | 1.24E+09 ± 1.88E+09 | 4.68E+07 ± 2.48E+07 | 11.49/*** |
| Inertia_angle135_offset4_CMP | 513.09 ± 398.40 | 1140 ± 636.53 | 340.58 ± 299.05 | 12.06/*** |
| uniformity_CMP | 0.43 ± 0.19 | 0.61 ± 0.09 | 0.36 ± 0.23 | 14.97/*** |
| ClusterProminence_angle0_offset7_CMP | 3.51E+07 ± 4.55E+07 | 9.12E+07 ± 5.63E+07 | 2.43E ± 0.7 ± 5E+07 | 8.97/*** |
| sumVariance_CMP | 0.04 ± 0.02 | 0.06 ± 0.02 | 0.02 ± 0.02 | 21.15/*** |
***Denotes statistical significance, p < 0.001
Fig. 3Comparison of ROC curves among CMP, NP, and combined models in the training (a–c) and testing sets (d–f)
The diagnostic performance of the radiomic models in the training set (n = 123)
| Classifier evaluation | CMP | NP | Combination | ||||||
|---|---|---|---|---|---|---|---|---|---|
| RO | chRCC | ccRCC | RO | chRCC | ccRCC | RO | chRCC | ccRCC | |
| Average AUC | 0.864 | 0.898 | 0.871 | 0.853 | 0.865 | 0.884 | 0.928 | 0.955 | 0.939 |
| 95% CI | 0.792, 0.937 | 0.828, 0.968 | 0.780, 0.962 | 0.724, 0.933 | 0.797, 0.933 | 0.800, 0.969 | 0.838, 0.997 | 0.913, 0.996 | 0.880, 0.997 |
| Balanced Accuracy | 0.822 | 0.918 | 0.863 | 0.845 | 0.832 | 0.900 | 0.928 | 0.940 | 0.943 |
| Average Sensitivity | 0.844 | 0.950 | 0.775 | 0.789 | 0.850 | 0.825 | 0.956 | 0.950 | 0.900 |
| Average Specificity | 0.800 | 0.886 | 0.971 | 0.900 | 0.814 | 0.957 | 0.900 | 0.929 | 0.986 |
AUC, the area under the curve. CI, confidence interval. CMP, corticomedullary phase. NP, nephrographic phase
The diagnostic performance of the radiomic models in the testing set (n = 57)
| Classifier evaluation | CMP | NP | Combination | ||||||
|---|---|---|---|---|---|---|---|---|---|
| RO | chRCC | ccRCC | RO | chRCC | ccRCC | RO | chRCC | ccRCC | |
| Average AUC | 0.949 | 0.953 | 0.929 | 0.888 | 0.845 | 0.901 | 0.939 | 0.906 | 0.959 |
| 95% CI | 0.878, 0.996 | 0.891, 0.998 | 0.859, 0.998 | 0.764, 0.997 | 0.730, 0.960 | 0.811, 0.991 | 0.855, 0.997 | 0.810, 0.998 | 0.911, 0.996 |
| Balanced Accuracy | 0.877 | 0.943 | 0.886 | 0.864 | 0.870 | 0.862 | 0.914 | 0.902 | 0.926 |
| Sensitivity | 0.854 | 0.950 | 0.905 | 0.927 | 0.900 | 0.857 | 0.927 | 0.900 | 0.952 |
| Specificity | 0.900 | 0.935 | 0.867 | 0.800 | 0.839 | 0.867 | 0.900 | 0.903 | 0.900 |
AUC, the area under the curve. CI, confidence interval. CMP, corticomedullary phase. NP, nephrographic phase
Fig. 4Summary plot of the impact features on the prediction of the SVM model. SHAP values of features in every sample. Each line represents a feature, and each dot represents a sample (a). The mean absolute value of the feature weight (b)
Fig. 5A radiomics nomogram incorporating the clinical feature, and a radiomics signature was developed in the training set (a). Calibration curves of the radiomics nomogram were used in the training set (b) and testing set (c). The y-axis represents the actual renal cell carcinoma rate, and the x-axis represents the predicted renal cell carcinoma possibility
The diagnostic performance of the nomogram in both the training and testing sets
| Training set | Testing set | |||
|---|---|---|---|---|
| Nomogram | Clinics | Nomogram | Clinics | |
| AUC (95%CI) | 0.990(0.970, 1.000) | 0.800(0.680, 0.930) | 0.950 (0.850, 1.000) | 0.630 (0.240, 1) |
| ACC (95%CI) | 0.947 (0.870, 0.985) | 0.750(0.637, 0.842) | 0.906 (0.750, 0.980) | 0.781 (0.600, 0.907) |
| Sensitivity | 0.949 | 0.763 | 0.931 | 0.821 |
| Specificity | 0.941 | 0.706 | 0.910 | 0.510 |
Fig. 6ROC curves of clinical and radiomics nomogram models in the training (a) and testing dataset (b). Decision curve analysis of the prediction models in the testing set (c). The y-axis measures the net benefit. The red line represents the radiomics nomogram. The green dotted line represents the assumption that all patients were renal cell carcinoma. The blue line represents the clinical prediction model. The red dotted line represents the radiomics model
Fig. 7Distribution of representative radiomics features and the post-hoc statistical results in the three groups (a–e). Pearson’s correlation coefficient heatmap of mutual analysis between the representative radiomics features and clinicopathologic protein (f). The values in the square lattices represent the magnitude of the r values of the correlation analysis displayed by color differences